Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy

References

• Czyz J, Hellmann A, Dziadziuszko R, et al High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transpl 2002;30:29–34.
   PubMed Web of Science ®Google Scholar
• André M, Henry-Amar M, Pico JL, et al Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure. J Clin Oncology 1999;17:222–229.
   PubMed Web of Science ®Google Scholar
• Engelhardt BG, Holland DW, Brandt SJ, et al High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes. Leuk Lymphoma 2007;48:1728–1735.
   PubMed Web of Science ®Google Scholar
• Lavoie JC, Connors JM, Phillips GL, et al High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473–1478.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Powels R, et al Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncology 2008;19:1312–1319.
   PubMed Web of Science ®Google Scholar
• Brice P. Managing relapsed and refractory Hodgkin Lymphoma. Br J Haematol 2008;141:3–13.
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-centre eight-year study of 155 patients. Blood 1993;81:1137–1145.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Bagin RG, Jagannath S, et al High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993;4:767–773.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al Aggressive conventional chemotherapy compared with high-dose chemotherapy with ASCT for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfeld D, Goldstone AH, et al Dose intensification in autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin's disease. Ann Oncol 1994;5:153–158.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Moinpour CM, Pauler DK, et al Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21:3512–3519.
   PubMed Web of Science ®Google Scholar
• Loge JH, Foss Abrahamsen A, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. Ann Oncology 1999;10:71–77.
   PubMed Web of Science ®Google Scholar
• Wettergren L, Björkholm M, Axdorph U, Bowling A, Langius-Eklöf A. Individual quality of life in long-term survivors of Hodgkin's lymphoma – a comparative study. Qual Life Res 2003;12:545–554.
   PubMed Web of Science ®Google Scholar
• Ruffer JU, Flechtner H, Tralls P, et al Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39:2179–2186.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fossa SD, Oldervoll L, et al Fatigue in long-term Hodgkin's disease survivors: a follow-up study. J Clin Oncol 2005;23:6587–6595.
   PubMed Web of Science ®Google Scholar
• Neben K, Hohaus S, Goldschmidt H, et al High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. Ann Hematol 2000;79:547–555.
   PubMed Web of Science ®Google Scholar
• König HH, Bernert S, Angermeyer MC. Health status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen 2000;67:173–182.
   Web of Science ®Google Scholar
• Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001;37:1345–1351.
   PubMed Web of Science ®Google Scholar
• Fox-Rushby J, Selai C. What concepts does the EQ-5D measure? Intentions and interpretations. In: Brooks R, Rabin R, de Charro F, editors. The measurement and valuation of health status using EQ-5D: A European perspective: Evidence from the EuroQol BIO MED Research Programme. Rotterdam: Kluwer Academic Publishers, 2003. pp 167–168.
   Google Scholar
• Greiner W, Claes C, Buschbach JJV, Graf von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005;6:124–130.
   PubMedGoogle Scholar
• Fayers P, Bottomley. A quality of life research within the EORTC – the EORTC QLQ-C30. Eur J Cancer 2005;38:125–133.
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Aaronson NK, Bjordal K, et al (2001). EORTC QLQ-C30 scoring manual, 3rd ed. Brussels: EORTC.
   Google Scholar
• Frick E, Borasio GD, Zehentner H, Fischer N, Bumeder I. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation. Psychooncology 2004;13:116–124.
   PubMed Web of Science ®Google Scholar
• Hacker ED, Ferrans CE. Quality of life immediately after peripheral blood stem cell transplantation. Cancer Nurs 2003;26:312–322.
   PubMed Web of Science ®Google Scholar
• Wettergren L, Sprangers M, Björkholm M, Langius-Eklöf A. Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument. Psychooncology 2008;1:338–346.
   Web of Science ®Google Scholar
• Jo JC, Kang BW, Jang G, et al BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin lymphoma patients: comparative analysis of efficacy and toxicity. Ann Oncology 2008;87:43–48.
   Google Scholar
• Puig N, De la Rubia J, Remigia MJ, et al Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk Lymphoma 2006;47:1488–1494.
   PubMed Web of Science ®Google Scholar
• Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrow Transplant 1997;20:1063–1067.
   PubMed Web of Science ®Google Scholar
• Johnston LJ, Stockerl-Goldstein KE, Hu WW, et al Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:555–562.
   PubMed Web of Science ®Google Scholar
• Conner-Spady BL, Cumming C, Nabholtz JM, Jacobs P, Stewart D. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005;36:251–259.
   PubMed Web of Science ®Google Scholar
• Peppercorn J, Herndon J IInd, Kornblith AB, et al Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer 2005;104:1580–1589.
   PubMed Web of Science ®Google Scholar
• Gulbrandsen N, Wisløff F, Brinch L, et al Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65–77.
   PubMed Web of Science ®Google Scholar
• Carlson LE, Koski T, Glück S. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. Bone Marrow Transpl 2001;27:989–998.
   PubMed Web of Science ®Google Scholar
• Reece DE, Nevill TJ, Sayegh A, et al Regimen related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etopside (VP16-213) (CBV) and CBV plus cicplatine (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 1999;23:1131–1138.
   PubMed Web of Science ®Google Scholar
• Rubio C, Hill ME, Milan S, O'Brian MER, Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease. Br J Cancer 1997;75:1044–1048.
   PubMed Web of Science ®Google Scholar
• Van Besien K. Toxicity of high dose BCNU: how much is too much? Leuk Lymphoma 2006;47:1447–1448.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Metcalfe TL, Gooley TA, et al High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer 2008;15;113(6):1344–1350.
   Web of Science ®Google Scholar
• Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncology 2002;13:209–217.
   PubMed Web of Science ®Google Scholar
• Goodman KA, Riedel E, Serrano V, et al Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol 2008;26:5240–5247.
   PubMed Web of Science ®Google Scholar
• Mols F, Vingerhoets AJJM, Coebergh JW, et al Better quality of life among 10–15 year survivors of Hodgkin's lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer 2006;42:2794–2801.
   PubMed Web of Science ®Google Scholar
• Wettergren L, Björkholm M, Axdorph U, Langius-Eklöf A. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res 2004;13:1369–1379.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 2006;42:327–333 [Epub 2005 Dec 27].
   PubMed Web of Science ®Google Scholar
• Greil R, Holzner B, Kemmler G, et al Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. Eur J Cancer 1999;35:698–706.
   PubMed Web of Science ®Google Scholar
• Norum J, Wist EA. Quality of life in survivors of Hodgkin's disease. Qual Life Res 1996;5:367–374.
   PubMed Web of Science ®Google Scholar